Navigation Links
Wine, women and... spirits, beer and breast cancer risk
Date:9/27/2007

Barcelona, Spain: One of the largest individual studies of the effects of alcohol on the risk of breast cancer has concluded that it makes no difference whether a woman drinks wine, beer or spirits (liquor) it is the alcohol itself (ethyl alcohol) and the quantity consumed that is likely to trigger the onset of cancer. The increased breast cancer risk from drinking three or more alcoholic drinks a day is similar to the increased breast cancer risk from smoking a packet of cigarettes or more a day

Speaking at a news briefing today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, Dr Arthur Klatsky said: Population studies have consistently linked drinking alcohol to an increased risk of female breast cancer, but there has been little data, most of it conflicting, about an independent role played by the choice of beverage type.

Dr Klatsky, adjunct investigator in the Division of Research, Kaiser Permanente Medical Care Program, Oakland, USA, and his colleagues studied the drinking habits of 70,033 multi-ethnic women who had supplied information during health examinations between 1978-1985. By 2004, 2,829 of these women had been diagnosed with breast cancer. In one analysis, the researchers compared the choice of drink amongst women who tended to favour one type of drink over another with women who had no clear preference. They also looked for any association between the frequency of drinking one type of alcoholic drink over another. Finally, they examined the role of total alcohol intake, comparing it with women who drank less than one alcoholic drink a day.

They found that there was no difference in the risk of developing breast cancer between wine, beer or spirits. Even when wine was divided into red and white, there was no difference. However, when they looked at the relationship between breast cancer risk and total alcohol intake, the researchers found that women who drank between one and two alcoholic drinks per
'/>"/>

Contact: Emma Mason
wordmason@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Wine, Women And Longevity
2. Transdermal HRT not cardioprotective in postmenopausal women with CAD
3. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
4. Starvation in pregnant women can cause heart disease to their children
5. Women suffer from sexual dysfunction too
6. Brisk Walking lowers memory loss in women
7. Young womens woes
8. Young womens woes
9. Women find difficulty in calling it Quits
10. FDA approves new device to treat womens bleeding disorder
11. Women recognise faces better
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10